Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BILR 355 Formulations in Healthy Volunteers
NCT02253940Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from time zero extrapolated to infinity up to 96 hours and Maximum measured concentration up to 96 hours. Started Oct 2006; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02253940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253940.